Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03960021
Other study ID # IB 2018-03
Secondary ID 2018-A01996-49
Status Completed
Phase N/A
First received
Last updated
Start date March 4, 2019
Est. completion date March 15, 2022

Study information

Verified date February 2024
Source Institut Bergonié
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Local percutaneous thermal ablation is frequently proposed in the management of metastatic diseases. Radiofrequency ablation (RFA) has demonstrated good results when the metastatic disease is limited and slowly evolving. The destruction of solid metastasis by RF leads to inflammatory and immunological mechanisms that remain poorly understood. These pathological events may influence the overall and anti-tumor host immune responses. The purpose of the study is to identify and quantify some immune mechanisms triggered by RFA of pulmonary metastases from colorectal cancer origin.


Description:

RFA could provide activatory signals and become a source of tumor antigens for the immune system. Generating a massive and transient release of antigens, RFA could boost lymphocyte proliferation and production of inflammatory cytokines in response to tumor extracts. Herein, the investigator aims to demonstrate that RFA can amplify the specific T cell response in metastatic cancer patients. In order to ensure this, he plans to assess and quantify tumor infiltrating lymphocytes through tumoral biopsies. He also plans to measure the CD4, CD8 and NK lymphocytes release, the circulating DNA and tumoral cells release, during RFA of lung metastases. On tumoral biopsies, the expression of PDL-1 ligand will also be evaluated and measured. Participants with bilateral metastases or with 5 or more unilateral metastases will be recruited. The two RFA interventions will be carried out within 4-6 weeks of each other. Blood samples and tumoral biopsies will be performed during each intervention. Biopsies will be performed on a metastasis before the thermal ablation. Blood samples will be performed just before RFA, 30 min after RFA and one day after. Analysis, identification and measure of lymphocytes release will be performed with flow cytometry. All analysis and measurements will be performed in the Bio-Pathology department of Institut Bergonié.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 15, 2022
Est. primary completion date April 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient older than 18 years-old. 2. OMS performance status = 2. 3. Colorectal cancer histologically established previously. 4. Primary tumor resected. 5. Lung metastasis: 1. Bilateral metastasis (or unilateral metastases that need to undergo the RF in two separate sessions due to the number of metastases = 5) 2. Maximal diameter = 4 cm, 3. non or slowly progressive, with or without chemotherapy, 4. eligible to RFA. 6. Thorax-abdomen-pelvis CT scan and PET scan: 1. performed within 8 weeks before inclusion 2. finding no more than 10 metastatic nodules (liver + lung or lung alone) 7. Maximum of 8 weeks between the last cycle of chemotherapy and the first RFA. 8. Decision of local treatment agreed at the multidisciplinary digestive tumor board. 9. Life expectancy = 3 months. 10. Voluntarily signed and dated written informed consent prior to any study specific procedure. 11. Patients with a French social security in compliance with the Law relating to biomedical research (Article 1121-11 of French Public Health Code). Exclusion Criteria: 1. Other than lung or liver metastases. 2. Contraindication to general anesthesia. 3. Contraindication to RFA: tumor location (< 1cm from the hilum), lung insufficiency (FEV/sec < 1l), 4. Pregnant or lactating women. 5. Concomitant participation to another interventional research. 6. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons. 7. Patient deprived of liberty or under legal protection measure.

Study Design


Intervention

Radiation:
RFA interventions
Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs = 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.

Locations

Country Name City State
France Institut Bergonie Bordeaux

Sponsors (2)

Lead Sponsor Collaborator
Institut Bergonié Groupement Interrégional de Recherche Clinique et d'Innovation

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immune response triggered by RFA: Change from rate of tumor infiltrating T lymphocytes on tumoral stroma measured before and after RFA1. Day 1
Primary Immune response triggered by RFA: Change from rate of tumor infiltrating T lymphocytes on tumoral stroma measured before and after RFA2. Week 6
Primary Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune Förster Resonance Energy Transfer (iFRET). Day 1
Primary Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune Förster Resonance Energy Transfer (iFRET). Day 2
Primary Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune Förster Resonance Energy Transfer (iFRET). Week 6
Secondary Immune response triggered by RFA: Distribution of blood factors related to the immune response of the kinetics of peripheral blood T lymphocytes subsets NK, CD4, CD8 and their activated receptor subgroups HLADR+, CD25+, CD38+ release before RFA1. Day 1
Secondary Immune response triggered by RFA: Change from baseline (before RFA1) blood factors related to the immune response of the kinetics of peripheral blood T lymphocytes subsets NK, CD4, CD8. Day 1
Secondary Immune response triggered by RFA: Change from baseline (before RFA1) blood factors related to the immune response of the kinetics of peripheral blood T lymphocytes subsets NK, CD4, CD8. Day 2
Secondary Immune response triggered by RFA: Change from baseline (before RFA2) blood factors related to the immune response of the kinetics of peripheral blood T lymphocytes subsets NK, CD4, CD8. Week 6
Secondary Rate of Circulating DNA and tumor cells. Day 1
Secondary Rate of Circulating DNA and tumor cells. Day 2
Secondary Rate of Circulating DNA and tumor cells. Week 6
Secondary Expression of PDL-1 ligand on tumor cells from biopsies. Day 1
Secondary Expression of PDL-1 ligand on tumor cells from biopsies. Week 6
Secondary Change from baseline size of RFA treated tumor sites at 3 months based on CT scanner. Month 3
Secondary Change from baseline size of RFA treated tumor sites at 6 months based on CT scanner. Month 6
Secondary Change from baseline size of RFA treated tumor sites at 9 months based on CT scanner. Month 9
Secondary Change from baseline size of RFA treated tumor sites at 12 months based on CT scanner. Month 12
Secondary Change from baseline metastatic disease at 3 months Month 3
Secondary Change from baseline metastatic disease at 6 months Month 6
Secondary Change from baseline metastatic disease at 9 months Month 9
Secondary Change from baseline metastatic disease at 12 months Month 12
See also
  Status Clinical Trial Phase
Recruiting NCT05074966 - The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts Phase 3
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Completed NCT04551001 - Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy N/A
Completed NCT04551014 - Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm N/A
Recruiting NCT04270500 - The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period N/A
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Not yet recruiting NCT04073680 - A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03567850 - Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC N/A
Recruiting NCT05870332 - Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
Completed NCT04534218 - Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Phase 2
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideâ„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Completed NCT04195646 - Computer Aided Detection of Polyps During Colonoscopy Procedures N/A
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A
Not yet recruiting NCT03261752 - New Genes in the Carcinogenesis of Colorectal Cancer
Terminated NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1